Meds & supplements › Nevirapine
Medicine · Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Nevirapine extended-release tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 6 years of age or older with a body…
Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗
WARNING: LIFE-THREATENING (INCLUDING FATAL) HEPATOTOXICITY and SKIN REACTIONS Severe, life-threatening, and in some cases fatal hepatotoxicity, particularly in the first 18 weeks, has been reported in patients treated with nevirapine. In some cases, patients presented with non-specific prodromal signs or symptoms of hepatitis and progressed to hepatic failure. These events are often associated with rash. Female sex and higher CD4+ cell counts at initiation of therapy place patients at increased risk; women with CD4+ cell counts greater than 250 cells/mm3, including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. However, hepatotoxicity associated with nevirapine use can occur in both sexes, all CD4+ cell counts and at any time during treatment. Hepatic failure has also been reported in patients without HIV taking nevirapine for post-exposure prophylaxis (PEP). Use of nevirapine for occupational and non-occupational PEP is contraindicated. Patients with signs or symptoms of hepatitis, or with increased transaminases combined with rash or other systemic symptoms, must discontinue nevirapine and seek medical evaluation immediately. SKIN REACTIONS: Severe, life-threatening skin reactions, including fatal cases, have occurred in patients treated with nevirapine. These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction. Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions must discontinue nevirapine and seek medical evaluation immediately. Transaminase levels should be checked immediately for all patients who develop a rash in the first 18 weeks of treatment. The 14-day lead-in period with immediate-release nevirapine tablets 200 mg daily dosing has been observed to decrease the incidence of rash and must be followed. MONITORING FOR HEPATOXICITY AND SKIN REACTIONS: Patients must be monitored intensively during the first 18 weeks of therapy with nevirapine to detect potentially life-threatening hepatotoxicity or skin reactions. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of these events. Do not restart nevirapine following clinical hepatitis, or transaminase elevations combined with rash or other systemic symptoms, or following severe skin rash or hypersensitivity reactions. In some cases, hepatic injury has progressed despite discontinuation of treatment. WARNING: LIFE-THREATENING (INCLUDING FATAL) HEPATOTOXICITY and SKIN REACTIONS See full prescribing information for complete boxed warning. • Fatal and non-fatal hepatotoxicity have been reported in patients taking nevirapine extended-release tablets. Discontinue immediately if cli
Nevirapine extended-release tablets are prescription HIV-1 medicine used with other HIV-1 medicines to treat HIV-1 (Human Immunodeficiency Virus 1) in adults and in children 15 days of age or older. HIV-1 is the virus that causes AIDS (Acquired Immune Deficiency Syndrome).
Nevirapine extended-release tablets is a prescription medicine used with other HIV-1 medicines to treat HIV-1 (Human Immunodeficiency Virus 1) in adults and in children 6 years of age or older based on the child’s weight and height.
Do not take nevirapine extended-release tablets:
Before taking nevirapine tablets, tell your doctor about all your or your child’s medical conditions, including if you or your child:
Pregnancy Registry: There is a pregnancy registry for women who take nevirapine tablets during pregnancy. The purpose of the registry is to collect information about the health of you and your baby. Talk to your doctor about how you can take part in this registry.
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Especially tell your doctor if you take St. John’s wort.
Nevirapine extended-release tablets can cause severe liver and skin problems that may lead to death. These problems can happen at any time during treatment, but your risk is higher during the first 18 weeks of treatment. Nevirapine extended-release tablets can cause serious side effects, including:
People who have higher CD4 + cell counts when they begin nevirapine extended-release tablets have a higher risk of liver problems, especially: o Women with CD4 + counts higher than 250 cells/mm 3. This group has the highest risk. o Men with CD4 + counts higher than 400 cells/mm 3.
Stop taking nevirapine extended-release tablets and call your doctor right away if you have any of the following symptoms of liver problems with or without a skin rash:
Starting nevirapine: 1. Your doctor should start you with 1 dose each day to lower your chance of getting a serious rash. It is important that you only take 1 dose of nevirapine each day for the first 14 days.
2. Day 15, you will take 1 dose of nevirapine 2 times a day.
Starting nevirapine extended-release tablets when this is the first time you are taking any form of nevirapine: 1. Your doctor should start you with 1 dose of nevirapine oral suspension or immediate-release nevirapine tablets each day to lower your risk of getting a serious rash. It is important that you only take 1 dose of nevirapine or immediate-release nevirapine tablets each day for the first 14 days.
2. Day 15, take nevirapine extended-release tablets 1 time a day as prescribed by your doctor. Switching from nevirapine oral suspension or immediate-release nevirapine tablets to nevirapine extended-release tablets:
Nevirapine may cause serious side effects, including:
Keep nevirapine extended-release tablets and all medicines out of the reach of children. General information about the safe and effective use of nevirapine. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use nevirapine extended-release tablets for a condition for which it was not prescribed. Do not give nevirapine extended-release tablets to other people, even if they have the same condition you have. It may harm them. You can ask your pharmacist or doctor for information about nevirapine extended-release tablets that is written for health professionals.
sofidex [Internet]. Daloreum; c2026. Nevirapine; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/nevirapine
sofidex. (2026, August 2). Nevirapine. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/nevirapine
Nevirapine. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/nevirapine
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.